PFMU
MREO

Privium Fund Management (UK)’s Mereo BioPharma MREO Stock Holding History

Privium Fund Management (UK)’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,726
Closed -$32.4K – 87
2023
Q3 		$32.4K Sell
24,726
-152,474
-86% -$202K 0.03% 76
2023
Q2 		$225K Hold
177,200
– – 0.18% 60
2023
Q1 		$131K Hold
177,200
– – 0.1% 59
2022
Q4 		$133K Hold
177,200
– – 0.1% 48
2022
Q3 		$153K Buy
+177,200
New +$217K 0.2% 49

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Privium Fund Management (UK)'s MREO Position: Q4 2023 in Review

Privium Fund Management (UK) sold out of Mereo BioPharma (MREO) in Q4 2023, closing a stake of 24,726 shares — an estimated $32.4K sold.

Privium Fund Management (UK) first reported a position in MREO in Q3 2022 and held it in 5 quarters. The position peaked at $225K in Q2 2023. 64 funds tracked by Wall St. Rank hold MREO as of Q4 2023.

  • Privium Fund Management (UK) reported no remaining Mereo BioPharma position as of Q4 2023 after selling out during the quarter.
  • Privium Fund Management (UK) sold 24,726 Mereo BioPharma shares in Q4 2023, an estimated $32.4K.
  • Privium Fund Management (UK) first reported a position in Mereo BioPharma in Q3 2022 and held it in 5 quarters.
  • Privium Fund Management (UK)'s Mereo BioPharma position peaked at $225K in Q2 2023.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2023.

Based on Privium Fund Management (UK)'s 13F filing for Q4 2023, filed 13 Feb 2024.